Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds Page 1

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company focused on harnessing the power of trained immunity to prevent and treat disease, today announced the closing of a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,548,060 shares of common stock issued by the Company on February 5, 2024 (the “Existing Warrants”), at a reduced exercise price of $1.50 per share. The shares of common stock issuable upon exercise of the Existing Warrants have been registered pursuant to an effective registration statement on Form S-1 (File No. 333-276232). The closing of the offering is expected to occur on or about August 22, 2024, subject to the satisfaction of customary closing conditions.

Roth Capital Partners is acting as financial advisor to the company for this transaction.